These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22166520)

  • 21. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France.
    Bonnet F; Balestre E; Thiébaut R; Morlat P; Pellegrin JL; Neau D; Dabis F;
    Clin Infect Dis; 2006 Feb; 42(3):411-7. PubMed ID: 16392091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.
    Mocroft A; Kirk O; Clumeck N; Gargalianos-Kakolyris P; Trocha H; Chentsova N; Antunes F; Stellbrink HJ; Phillips AN; Lundgren JD
    Cancer; 2004 Jun; 100(12):2644-54. PubMed ID: 15197808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microcirculatory vascular dysfunction in HIV-1 infected patients receiving highly active antiretroviral therapy.
    Palios J; Ikonomidis I; Lekakis J; Tsiodras S; Poulakou G; Antoniadou A; Panagopoulos P; Papadopoulos A; Giamarellou H; Anastasiou-Nana M; Kremastinos D
    Microcirculation; 2010 May; 17(4):303-10. PubMed ID: 20536743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus.
    Sabio JM; Vargas-Hitos J; Zamora-Pasadas M; Mediavilla JD; Navarrete N; Ramirez A; Hidalgo-Tenorio C; Jáimez L; Martín J; Jiménez-Alonso J;
    J Rheumatol; 2009 Oct; 36(10):2204-11. PubMed ID: 19723903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
    Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
    J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The predictive value of brachial-ankle pulse wave velocity in coronary atherosclerosis and peripheral artery diseases in urban Chinese patients.
    Xu Y; Wu Y; Li J; Ma W; Guo X; Luo Y; Hu D
    Hypertens Res; 2008 Jun; 31(6):1079-85. PubMed ID: 18716354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoadiponectinemia in lipodystrophic HIV individuals: a metabolic marker of subclinical cardiac damage.
    Bezante GP; Briatore L; Rollando D; Maggi D; Setti M; Ghio M; Agosti S; Murdaca G; Balbi M; Barsotti A; Cordera R
    Nutr Metab Cardiovasc Dis; 2009 May; 19(4):277-82. PubMed ID: 19422999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study.
    Brown TT; Cole SR; Li X; Kingsley LA; Palella FJ; Riddler SA; Visscher BR; Margolick JB; Dobs AS
    Arch Intern Med; 2005 May; 165(10):1179-84. PubMed ID: 15911733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
    Hogg RS; Yip B; Kully C; Craib KJ; O'Shaughnessy MV; Schechter MT; Montaner JS
    CMAJ; 1999 Mar; 160(5):659-65. PubMed ID: 10102000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral lesions and immune reconstitution syndrome in HIV+/AIDS patients receiving highly active antiretroviral therapy. Epidemiological evidence.
    Gaitan Cepeda LA; Ceballos Salobreña A; López Ortega K; Arzate Mora N; Jiménez Soriano Y
    Med Oral Patol Oral Cir Bucal; 2008 Feb; 13(2):E85-93. PubMed ID: 18223535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical manifestations of treatment-naive patients with acquired immunodeficiency syndrome and responses to highly active antiretroviral therapy in the Taipei Veterans General Hospital: a 5-year prospective study.
    Hsu SF; Yang SP; Chan YJ; Wang YW
    J Microbiol Immunol Infect; 2011 Jun; 44(3):198-203. PubMed ID: 21524614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
    Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
    Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
    Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
    Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection.
    Visnegarwala F; Chen L; Raghavan S; Tedaldi E
    J Infect; 2005 May; 50(4):331-7. PubMed ID: 15845431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators.
    Girard PM; Guiguet M; Bollens D; Goderel I; Meyohas MC; Lecomte I; Raguin G; Frottier J; Rozenbaum W; Jaillon P
    Clin Infect Dis; 2000 Oct; 31(4):987-94. PubMed ID: 11049781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.